Samsung Group to invest $356 billion in biopharmaceutical and semiconductor manufacturing

Samsung Group will invest $356 billion over the next five years in semiconductors, biopharmaceuticals and other next-generation technologies. The bulk of the investment, 80%, will be made in South Korea. The investments will help the company ensure long-term growth in the microchip and biopharmaceutical sectors.